Loading...
XKRX
083790
Market cap40mUSD
Jul 10, Last price  
899.00KRW
1D
2.04%
1Q
-31.06%
Jan 2017
-92.97%
IPO
-92.78%
Name

CrystalGenomics Inc

Chart & Performance

D1W1MN
XKRX:083790 chart
P/E
—
P/S
2.26
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.73%
Rev. gr., 5y
-1.95%
Revenues
27.39b
+277.64%
4,795,861,7404,535,574,6106,135,999,74014,524,948,95012,175,117,57013,887,490,84014,006,559,00030,223,480,00042,376,294,0004,321,330,0004,878,663,0007,253,270,00027,391,445,000
Net income
-3.52b
L-93.17%
-11,405,566,000-11,930,796,000-4,849,955,000-2,179,460,000-8,575,453,0006,907,591,480-37,585,388,000-9,837,975,000-15,900,734,000-23,868,947,000-48,923,631,000-51,544,107,000-3,520,967,000
CFO
-17.41b
L-32.64%
-6,274,189,270-3,754,869,220-4,665,135,600-8,302,347,0901,632,902,770-1,206,721,920-7,137,542,830-16,384,882,000-11,458,251,000-24,404,574,000-32,408,446,000-25,850,202,000-17,412,712,000
Dividend
Mar 15, 20220.285 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CG Invites Co., Ltd., based in Seoul, South Korea, specializes in the groundbreaking discovery and progression of novel medical treatments. Founded on July 7, 2000, by Cho Joong Myung and Ro Seong Gu, the company's operations are divided into two main areas. Its Pharmaceutical Research and Development segment primarily focuses on utilizing digital genomics for drug innovation. Additionally, the Automation Equipment division is responsible for manufacturing machinery, including hot pack and printed circuit board (PCB) equipment.
URL
http://www.crystalgenomics.com/
IPO date
Jan 06, 2006
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑082017‑082016‑08
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT